All In MedTech

Device Trial Radar · NCT07858539

Laser Atherectomy and Sirolimus-eluting Balloon Angioplasty for CLTI

LASER Atherectomy and Sirolimus-eluting Balloon Angioplasty for Chronic Limb-threatening Ischemia: The LASER-S Study

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

55

Actual

Start

Apr 1, 2025

Primary completion

Nov 17, 2026

Study completion Nov 17, 2026

Sponsor

Lead sponsor
Attikon HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 5, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Peripheral arterial disease (PAD) is a widespread pathology affecting over 200 million adults globally and is primarily caused by atherosclerosis. It leads to peripheral arterial stenosis, commonly in the lower extremities, resulting in symptoms ranging from intermittent claudication to chronic limb-threatening ischemia (CLTI). Endovascular interventions are currently considered first-line treatment approaches for PAD. Laser atherectomy offers a minimally invasive endovascular option to effectively debulk atherosclerotic steno-occlusive lesions prior to balloon angioplasty, minimizing vessel dissection and the need for stenting. Additionally, recent multicenter randomized controlled trials have demonstrated that sirolimus-eluting balloon (SEB) angioplasty is a safe and effective treatment method for PAD. Although safety and efficacy of both laser atherectomy and SCBs are recognized, their combination for the treatment of patients with CLTI has not been adequately investigated. This research pilot study aimed to evaluate the safety and efficacy of combined laser atherectomy and SCB angioplasty for the treatment of CLTI. Key endpoints of the study include technical success rate, major adverse events, rates of limb salvage and target lesion reintervention, clinical improvement and overall patient survival rate.

Conditions

  • Chronic Limb Threatening Ischemia

Interventions

  • Laser atherectomy followed by Sirolimus-eluting balloon angioplasty of femoropopliteal or infrapopliteal or both arterial stenosis or occlusionsDevice

    Laser atherectomy followed by Sirolimus-eluting balloon angioplasty of femoropopliteal and/or infrapopliteal arterial lesions (stenosis or occlusions) using the Auryon laser atherectomy system (Angiodynamics, USA) and the SELUTION sirolimus-eluting balloon catheter (Cordis, USA).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Limb salvageTime frame: 6 months
  2. Clinically-driven target lesion reintervention (CD-TLR)Time frame: 6 months
  3. Major adverse events (MAE)Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • "ATTIKON" University General Hospital, , 1st Rimini St,

    Athens, Select A State, Greece

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.